You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明巨諾-B(02126.HK):倍諾達®針對兒童及年輕成人的臨牀試驗申請獲批
格隆匯 04-20 18:03

格隆匯4月20日丨 藥明巨諾-B(02126.HK)宣佈,其靶向CD19的自體嵌合抗原受體T("CAR-T")細胞免疫治療產品倍諾達®(瑞基奧侖賽注射液)用於治療兒童及年輕成人復發或難治性B細胞急性淋巴細胞白血病("r/rB-ALL")的臨牀試驗申請已獲得中國國家藥品監督管理局("中國藥監局")的默示許可。

B細胞急性淋巴細胞白血病("B-ALL")是兒童最常見的惡性腫瘤,對化療藥物的耐藥通常導致患者復發或疾病進展,而復發後的患者往往生存率極差。挽救性化療雖然是可選擇的治療方案,但對於侵襲性強的復發難治患者療效差,較低的緩解率以及較高的再複發率導致挽救性化療後的患者生存率非常有限。針對r/rB-ALL目前無標準的有效治療手段,即使進行了異基因造血幹細胞移植,其長期生存率仍然不樂觀,給臨牀治療帶來巨大挑戰,r/rB-ALL患者的長期生存仍亟待新的治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account